Quick Takeaways
- Vestal Point Capital, LP filed SCHEDULE 13G/A for Dianthus Therapeutics, Inc. /DE/ Common Stock, par value $0.001 per share (DNTH).
- Disclosed ownership: 3%.
- Date of event: 30 Sep 2025.
Vestal Point Capital, LP - 30 Sep 2025 SCHEDULE 13G/A Report for Dianthus Therapeutics, Inc. /DE/ Common Stock, par value $0.001 per share (DNTH)
- Filing Manager
- Vestal Point Capital, LP
- Reporting Manager
- Vestal Point Capital, LP
- Symbol
- DNTH
- Shares outstanding
- 39,333,333 shares
- Disclosed Ownership
- 1,180,000 shares
- Ownership
- 3%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 16:06:28 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Vestal Point Capital, LP disclosed 3% ownership in Dianthus Therapeutics, Inc. /DE/ Common Stock, par value $0.001 per share (DNTH) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 14 Aug 2025.
- Current filing was accepted on 14 Nov 2025, 16:06.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Vestal Point Capital, LP | 3% | 1,180,000 | 0 | 1,180,000 | /s/ Ryan Wilder | By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner | |
| Ryan Wilder | 3% | 1,180,000 | 0 | 1,180,000 | /s/ Ryan Wilder | Ryan Wilder, Individually |